News & Events Press Release
May 31, 2017

Stockholm, Sweden – May 31, 2017. Pharmalink AB, a specialty pharma company, is pleased to announce that its recent publication in The Lancet on the positive Phase 2b trial of Nefecon® in primary IgA nephropathy (IgAN) patients, has been selected for presentation at the upcoming European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) conference (Madrid, Spain; June 3-6, 2017).

The Phase 2b trial (known as the NEFIGAN trial), will be presented in a special session co-hosted by The Lancet by lead author Bengt Fellström, MD, PhD, Professor of Nephrology at Uppsala University Hospital and Principal Investigator of the NEFIGAN Trial.

Title: Effects of a novel targeted release formulation of budesonide vs. placebo in IgA nephropathy: The NEFIGAN randomised clinical trial.

Session: The Lancet/ERA-EDTA Symposium

Date: Sunday, June 4, 2017

Time: 15:15-16:45 CET

Location: Hall 10.A

Prof. Fellström will give a second presentation of results from the NEFIGAN trial at the conference.

Title: Proteinuria reduction in IgA nephropathy by Nefecon, a targeted release formulation of budesonide - results from the NEFIGAN trial

Session: Glomerulonephritis

Date: Tuesday, June 6, 2017

Time: 8.00-9.30 CET

Location: Sala Neptuno